September 08, 2023

GenomeWeb→

September 08, 2023/ Guest User

Biological Dynamics Partners With Pancreatic Cancer Consortium On Early Detection Study

Biological Dynamics said this week that it has partnered with the Pancreatic Cancer Early Detection (PRECEDE) Consortium for a validation study of its ExoVita pancreas assay, an exosome-derived blood-based test utilizing the firm's Verita platform.

Biological Dynamics - Exosome Tell The Story

Biological Dynamics is a private molecular diagnostics company located in San Diego. Our proprietary technology offers a novel, fast, and cost-effective lab-on-chip ACE platform that isolates nanoparticles from high conductance physiological solutions.
Our product, the TR(ACE)™ assay, will utilize the platform for monitoring treatment response in oncology. TR(ACE)™ has not been cleared or approved by the U.S. FDA or any foreign regulatory agency.

The ExoVerita™ Pro instrument and ExoVita™ Pancreas test described is for Research Use Only. Not for diagnostic purposes.
Biological Dynamics’s Clinical Laboratory is CLIA-certified and CAP accredited.

Media

Biological Dynamics - Exosome Tell The Story